{
    "hands_on_practices": [
        {
            "introduction": "Before a new drug candidate enters clinical trials, scientists must predict its behavior in the human body based on its fundamental properties. This exercise demonstrates how to integrate physicochemical data, such as the acid dissociation constant ($pK_a$), solubility ($S_0$), and partition coefficient ($\\log P$), with a model of the gastrointestinal environment to forecast oral absorption. By calculating outcomes like supersaturation and precipitation risk, this practice illustrates a core task in \"developability assessment,\" which aims to identify and mitigate potential liabilities of a new molecule before major resources are invested .",
            "id": "4598089",
            "problem": "A new orally administered monoprotic weak base is entering Investigational New Drug-enabling studies aimed at predicting absorption-limited exposure from fundamental properties and the gastrointestinal (GI) pH environment. The compound has acid dissociation constant $pK_{a} = 6.8$, partition coefficient $\\log P = 3.0$, and intrinsic solubility (defined as the solubility of the neutral species) $S_{0} = 0.001$ mg/mL. An immediate-release $100$ mg dose is administered with $250$ mL water. Assume the following gastrointestinal transit and environment: the stomach is at pH $1.5$ with volume $250$ mL, and gastric emptying delivers the entire dissolved content to the small intestine, which is well mixed at pH $6.5$ with volume $500$ mL. Assume the small intestinal absorption window is $2.0$ hours. \n\nFor passive permeability across the intestinal epithelium, model the effective permeability-surface area product of the unionized species using the empirical relation $PS_{u} = \\kappa \\times 10^{\\log P}$ with $\\kappa = 1.0 \\times 10^{-3}$ cm$^{3}$/s. Assume the ionized species has negligible permeability relative to the unionized species, so that the effective permeability-surface area product is $PS_{\\text{eff}} = f_{u} \\times PS_{u}$, where $f_{u}$ is the fraction of drug in the unionized (neutral) form at the local pH. Treat the stomach as a dissolution compartment only (no gastric absorption). Assume rapid acid-base equilibrium and rapid solidâ€“liquid equilibrium such that upon transfer from stomach to intestine, any supersaturation at the intestinal pH instantaneously relaxes to the equilibrium solubility at that pH (precipitation removes excess). Assume dissolution from precipitated solid is fast enough to maintain the luminal dissolved concentration at the equilibrium solubility in the small intestine over the absorption window as long as solid remains. \n\nStarting from acid-base equilibria for a monoprotic weak base and mass transfer by passive diffusion, and using the GI pH profile above:\n- Compute the unionized fraction $f_{u}$ in the stomach and small intestine.\n- Compute the pH-dependent solubility in the stomach and small intestine using the intrinsic solubility and acid-base equilibria.\n- Determine the initial intestinal concentration after mixing gastric contents into the intestinal volume, and compute the supersaturation ratio relative to the intestinal equilibrium solubility to assess precipitation risk.\n- Under the stated assumptions, compute the total mass absorbed from the small intestine over the $2.0$ hour window and thereby the predicted fraction of the dose absorbed (a unitless decimal). \n\nExpress the final answer as the predicted fraction of dose absorbed as a decimal. Round your final answer to three significant figures.",
            "solution": "The user has provided a problem in clinical pharmacology that requires a quantitative prediction of drug absorption based on physicochemical properties and gastrointestinal (GI) physiology.\n\n### Step 1: Extract Givens\n- Drug type: Monoprotic weak base\n- Acid dissociation constant: $pK_a = 6.8$\n- Partition coefficient: $\\log P = 3.0$\n- Intrinsic solubility (of neutral species): $S_0 = 0.001$ mg/mL\n- Dose: $M_{dose} = 100$ mg\n- Administration volume: $V_{water} = 250$ mL\n- Stomach conditions: $pH_{stomach} = 1.5$, $V_{stomach} = 250$ mL\n- Small intestine conditions: $pH_{intestine} = 6.5$, $V_{intestine} = 500$ mL\n- Absorption window: $T = 2.0$ hours\n- Permeability-surface area product of unionized species: $PS_u = \\kappa \\times 10^{\\log P}$ with $\\kappa = 1.0 \\times 10^{-3}$ cm$^3$/s\n- Effective permeability-surface area product: $PS_{\\text{eff}} = f_u \\times PS_u$\n- Ionized species permeability is negligible.\n- No gastric absorption.\n- Gastric emptying transfers all dissolved content to the small intestine.\n- Instantaneous precipitation to equilibrium solubility in the intestine.\n- Rapid dissolution maintains saturated concentration in the intestine as long as solid drug is present.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded**: The problem is based on fundamental principles of physical chemistry and biopharmaceutics, including acid-base equilibria (Henderson-Hasselbalch equation), solubility, the pH-partition hypothesis of drug absorption, and mass transfer kinetics. The assumptions are standard simplifications used in compartmental absorption models.\n- **Well-Posed**: The problem provides all necessary parameters and a clear set of assumptions to calculate a unique, quantitative answer for the fraction of dose absorbed.\n- **Objective**: The problem is stated in precise, quantitative, and unbiased language.\n- **Completeness and Consistency**: The problem is self-contained. The units are consistent: volumes are in mL, mass in mg, concentration in mg/mL. The constant $\\kappa$ is in cm$^3$/s, where $1$ cm$^3 = 1$ mL. The time units (hours for the window, seconds for the rate constant) are reconcilable.\n\n### Step 3: Verdict and Action\nThe problem is valid. A complete, reasoned solution will be provided.\n\n### Solution Derivation\n\nThe problem requires a step-by-step calculation of the fraction of a drug dose absorbed from the small intestine. This involves analyzing the drug's state in the stomach, its transition to the intestine, and its subsequent absorption.\n\n**1. Unionized Fraction ($f_u$)**\n\nThe drug is a monoprotic weak base. Its protonation equilibrium is $B + H^+ \\rightleftharpoons BH^+$, where $B$ is the unionized base and $BH^+$ is the ionized conjugate acid. The Henderson-Hasselbalch equation for the conjugate acid is:\n$$pH = pK_a + \\log_{10} \\left( \\frac{[B]}{[BH^+]} \\right)$$\nThe fraction of the drug in the unionized form, $f_u$, is given by:\n$$f_u = \\frac{[B]}{[B] + [BH^+]} = \\frac{1}{1 + \\frac{[BH^+]}{[B]}}$$\nFrom the Henderson-Hasselbalch equation, $\\frac{[BH^+]}{[B]} = 10^{(pK_a - pH)}$. Thus,\n$$f_u = \\frac{1}{1 + 10^{(pK_a - pH)}}$$\n- In the stomach ($pH_{stomach} = 1.5$ with $pK_a = 6.8$):\n$$f_{u, stomach} = \\frac{1}{1 + 10^{(6.8 - 1.5)}} = \\frac{1}{1 + 10^{5.3}}$$\nThis is a very small fraction, indicating the drug is almost entirely ionized in the stomach.\n\n- In the small intestine ($pH_{intestine} = 6.5$ with $pK_a = 6.8$):\n$$f_{u, intestine} = \\frac{1}{1 + 10^{(6.8 - 6.5)}} = \\frac{1}{1 + 10^{0.3}}$$\n\n**2. pH-Dependent Solubility ($S_{pH}$)**\n\nThe total solubility, $S_{pH}$, is the sum of the dissolved unionized species ($S_0$) and the dissolved ionized species in a saturated solution.\n$$S_{pH} = [B]_{sat} + [BH^+]_{sat} = S_0 + S_0 \\times 10^{(pK_a - pH)} = S_0 (1 + 10^{(pK_a - pH)})$$\n- In the stomach ($pH_{stomach} = 1.5$):\n$$S_{stomach} = S_0 (1 + 10^{(6.8 - 1.5)}) = (0.001 \\text{ mg/mL}) \\times (1 + 10^{5.3})$$\n$$S_{stomach} \\approx (0.001) \\times (1 + 199526) \\approx 199.5 \\text{ mg/mL}$$\nThe maximum mass that can be dissolved in the stomach volume ($V_{stomach} = 250$ mL) is:\n$$M_{dissolved, stomach} = S_{stomach} \\times V_{stomach} \\approx 199.5 \\text{ mg/mL} \\times 250 \\text{ mL} = 49875 \\text{ mg}$$\nSince $M_{dissolved, stomach} \\gg M_{dose} = 100$ mg, the entire dose dissolves in the stomach.\n\n- In the small intestine ($pH_{intestine} = 6.5$):\n$$S_{intestine} = S_0 (1 + 10^{(6.8 - 6.5)}) = (0.001 \\text{ mg/mL}) \\times (1 + 10^{0.3})$$\nUsing $10^{0.3} \\approx 1.99526$:\n$$S_{intestine} \\approx 0.001 \\times (1 + 1.99526) = 0.00299526 \\text{ mg/mL}$$\n\n**3. Intestinal Concentration and Supersaturation**\n\nThe entire dissolved dose ($100$ mg) is emptied into the intestinal volume ($V_{intestine} = 500$ mL). The initial concentration, if no precipitation occurred, would be:\n$$C_{initial, intestine} = \\frac{M_{dose}}{V_{intestine}} = \\frac{100 \\text{ mg}}{500 \\text{ mL}} = 0.2 \\text{ mg/mL}$$\nThe supersaturation ratio (SR) is the ratio of this initial concentration to the equilibrium solubility in the intestine:\n$$SR = \\frac{C_{initial, intestine}}{S_{intestine}} = \\frac{0.2 \\text{ mg/mL}}{0.001 \\times (1 + 10^{0.3}) \\text{ mg/mL}} = \\frac{200}{1 + 10^{0.3}} \\approx \\frac{200}{2.99526} \\approx 66.8$$\nSince $SR > 1$, the solution is supersaturated. The problem states that precipitation occurs instantaneously, reducing the luminal concentration to the equilibrium solubility. Therefore, the concentration of dissolved drug in the intestine is maintained at:\n$$C_{lumen} = S_{intestine} = S_0 (1 + 10^{0.3})$$\nThis concentration is maintained as long as precipitated solid drug is present to redissolve and replace the absorbed drug.\n\n**4. Absorption Rate and Total Mass Absorbed**\n\nThe rate of absorption is given by the product of the effective permeability-surface area product and the luminal concentration of the drug. The problem specifies that only the unionized form is permeable.\n$$\\frac{dM_{absorbed}}{dt} = PS_{\\text{eff}} \\times C_{lumen}$$\nwhere $PS_{\\text{eff}} = f_{u, intestine} \\times PS_u$.\nSubstituting the expressions for $PS_{\\text{eff}}$, $f_{u, intestine}$, and $C_{lumen}$:\n$$\\frac{dM_{absorbed}}{dt} = (f_{u, intestine} \\times PS_u) \\times S_{intestine}$$\n$$\\frac{dM_{absorbed}}{dt} = \\left( \\frac{1}{1 + 10^{(pK_a - pH_{intestine})}} \\times PS_u \\right) \\times \\left( S_0 (1 + 10^{(pK_a - pH_{intestine})}) \\right)$$\nThe term $(1 + 10^{(pK_a - pH_{intestine})})$ cancels out, yielding a constant absorption rate:\n$$\\frac{dM_{absorbed}}{dt} = PS_u \\times S_0$$\nThis is a key simplification for solubility-limited absorption. We now calculate the numerical values.\nFirst, calculate $PS_u$:\n$$PS_u = \\kappa \\times 10^{\\log P} = (1.0 \\times 10^{-3} \\text{ cm}^3/\\text{s}) \\times 10^{3.0}$$\n$$PS_u = (1.0 \\times 10^{-3} \\text{ cm}^3/\\text{s}) \\times 1000 = 1.0 \\text{ cm}^3/\\text{s}$$\nSince $1$ cm$^3 = 1$ mL, $PS_u = 1.0$ mL/s.\nNow, calculate the absorption rate:\n$$\\text{Rate} = PS_u \\times S_0 = (1.0 \\text{ mL/s}) \\times (0.001 \\text{ mg/mL}) = 0.001 \\text{ mg/s}$$\nThis rate is constant as long as solid drug is available. The amount of precipitated drug is $M_{precipitated} = (C_{initial, intestine} - S_{intestine}) \\times V_{intestine} = (0.2 - 0.002995) \\times 500 \\approx 98.5$ mg, which is substantial.\n\nThe total mass absorbed over the $T = 2.0$ hour window is the integral of this rate over time.\nThe time window in seconds is $T = 2.0 \\text{ h} \\times 3600 \\text{ s/h} = 7200$ s.\n$$M_{absorbed} = \\text{Rate} \\times T = (0.001 \\text{ mg/s}) \\times (7200 \\text{ s}) = 7.2 \\text{ mg}$$\nSince $7.2$ mg is much less than the precipitated mass, the assumption of a constant rate is valid for the entire window.\n\n**5. Fraction of Dose Absorbed ($F_a$)**\n\nThe fraction of the dose absorbed is the ratio of the mass absorbed to the total dose administered:\n$$F_a = \\frac{M_{absorbed}}{M_{dose}} = \\frac{7.2 \\text{ mg}}{100 \\text{ mg}} = 0.072$$\nRounding to three significant figures, the final answer is $0.0720$.",
            "answer": "$$\\boxed{0.0720}$$"
        },
        {
            "introduction": "The transition from preclinical studies to the first-in-human (FIH) trial is a critical milestone where theoretical predictions are first tested in practice. This problem focuses on a cornerstone of FIH planning: calculating the initial dosing regimen required to achieve a therapeutic target concentration based on fundamental pharmacokinetic principles. You will apply the steady-state mass balance equation and, importantly, assess how uncertainty in key parameters like oral bioavailability ($F$) can impact dose selection, a crucial consideration for ensuring safety in early clinical development .",
            "id": "4598103",
            "problem": "A new extended-release oral small-molecule is transitioning from preclinical studies to first-in-human (FIH) evaluation. Physiologically based pharmacokinetic (PBPK) modeling predicts a human systemic clearance ($CL$) of $7.2$ L/h. A once-every-$12$-hour dosing interval, denoted by $\\tau = 12$ h, is planned. The formulation has sustained input designed to minimize peak-to-trough fluctuation; the predicted terminal half-life is $t_{1/2} = 18$ h, which is longer than the dosing interval ($t_{1/2} > \\tau$), so the steady-state trough concentration is expected to be close to the steady-state average concentration, with deviation under approximately $10\\%$. The minimum efficacious concentration (MEC) inferred from pharmacodynamic models is $1.1$ mg/L, and the clinical team wishes to target a steady-state trough of $1.1$ mg/L to ensure the concentration does not fall below the MEC. The nominal oral bioavailability ($F$) expected for the extended-release capsule is $0.42$, based on preclinical dog studies, but there is uncertainty: a plausible range is $0.30$ to $0.60$ due to potential formulation and interspecies differences.\n\nUsing first principles of steady-state mass balance for linear pharmacokinetics, compute the single dose administered every $\\tau$ hours that achieves a steady-state trough concentration of $1.1$ mg/L under the approximation $C_{\\text{ss,trough}} \\approx C_{\\text{ss,avg}}$. Express your final answer in mg and round your answer to four significant figures.\n\nThen, in your reasoning, discuss the sensitivity of the required dose to uncertainty in oral bioavailability ($F$) in FIH planning and quantify the fractional change in the required dose if the true $F$ is $0.30$ instead of $0.42$. Your final numerical answer should be only the computed dose per dosing interval.",
            "solution": "The problem is valid as it is scientifically grounded in the principles of clinical pharmacokinetics, is well-posed with sufficient and consistent data, and is expressed objectively.\n\nThe fundamental principle for determining a maintenance dosing regimen for a drug exhibiting linear pharmacokinetics is the concept of mass balance at steady state. At steady state ($ss$), the rate at which the drug is administered and absorbed into the systemic circulation must equal the rate at which it is eliminated from the body.\n\nThe average rate of drug administration into the systemic circulation (Rate In) for an oral drug with dose $D$, dosing interval $\\tau$, and oral bioavailability $F$ is given by:\n$$ \\text{Rate In} = \\frac{F \\times D}{\\tau} $$\nThe average rate of drug elimination from the body (Rate Out) is the product of the systemic clearance ($CL$) and the average steady-state plasma concentration ($C_{\\text{ss,avg}}$):\n$$ \\text{Rate Out} = CL \\times C_{\\text{ss,avg}} $$\nAt steady state, we equate these two rates:\n$$ \\frac{F \\times D}{\\tau} = CL \\times C_{\\text{ss,avg}} $$\nThe problem asks to calculate the dose $D$ required to achieve a target steady-state trough concentration ($C_{\\text{ss,trough}}$) of $1.1$ mg/L. A crucial piece of information is that the drug's predicted terminal half-life ($t_{1/2} = 18$ h) is longer than the dosing interval ($\\tau = 12$ h). For an extended-release formulation under such conditions ($t_{1/2} > \\tau$), the fluctuation between peak and trough concentrations at steady state is minimal. The problem statement formalizes this by providing the approximation that the trough concentration is nearly equal to the average concentration:\n$$ C_{\\text{ss,trough}} \\approx C_{\\text{ss,avg}} $$\nTherefore, we can set our target average steady-state concentration to be the target trough concentration:\n$$ C_{\\text{ss,avg}} = 1.1 \\, \\text{mg/L} $$\nNow, we can solve the steady-state mass balance equation for the dose $D$:\n$$ D = \\frac{CL \\times C_{\\text{ss,avg}} \\times \\tau}{F} $$\nThe problem provides the following values:\n- Systemic clearance, $CL = 7.2$ L/h\n- Dosing interval, $\\tau = 12$ h\n- Target average concentration, $C_{\\text{ss,avg}} = 1.1$ mg/L\n- Nominal oral bioavailability, $F = 0.42$\n\nSubstituting these values into the equation for the dose:\n$$ D = \\frac{(7.2 \\, \\text{L/h}) \\times (1.1 \\, \\text{mg/L}) \\times (12 \\, \\text{h})}{0.42} $$\nThe units are consistent: $\\frac{(\\text{L/h}) \\times (\\text{mg/L}) \\times \\text{h}}{\\text{dimensionless}} = \\text{mg}$.\n$$ D = \\frac{95.04 \\, \\text{mg}}{0.42} $$\n$$ D = 226.285714... \\, \\text{mg} $$\nRounding to four significant figures as requested, the required dose is $226.3$ mg.\n\nRegarding the sensitivity of the required dose to the uncertainty in oral bioavailability ($F$), the dose equation $D = \\frac{CL \\times C_{\\text{ss,avg}} \\times \\tau}{F}$ shows that $D$ is inversely proportional to $F$. This inverse relationship is a critical consideration in first-in-human (FIH) planning. The plausible range for $F$ is given as $0.30$ to $0.60$. This uncertainty in $F$ translates directly into a wide range of possible doses required to achieve the therapeutic target. For instance:\n- If $F = 0.30$ (worst-case absorption): $D = \\frac{95.04}{0.30} = 316.8$ mg.\n- If $F = 0.60$ (best-case absorption): $D = \\frac{95.04}{0.60} = 158.4$ mg.\nThe dose required to meet the target concentration could be nearly $40\\%$ higher or $30\\%$ lower than the dose calculated with the nominal $F$. This highlights a significant risk: if the true $F$ is higher than the nominal value of $0.42$, administering the calculated dose of $226.3$ mg could lead to unexpectedly high and potentially toxic concentrations. Conversely, if the true $F$ is lower, the dose may be sub-therapeutic.\n\nTo quantify the fractional change in the required dose if the true $F$ is $0.30$ instead of the nominal $0.42$, we can calculate the ratio. Let $D_{nominal}$ be the dose for $F_{nominal} = 0.42$ and $D_{new}$ be the dose for $F_{new} = 0.30$.\n$$ \\text{Fractional Change} = \\frac{D_{new} - D_{nominal}}{D_{nominal}} $$\nSince $D$ is proportional to $1/F$, this simplifies to:\n$$ \\text{Fractional Change} = \\frac{\\frac{k}{F_{new}} - \\frac{k}{F_{nominal}}}{\\frac{k}{F_{nominal}}} = \\frac{F_{nominal}}{F_{new}} - 1 $$\nwhere $k = CL \\times C_{\\text{ss,avg}} \\times \\tau$.\n$$ \\text{Fractional Change} = \\frac{0.42}{0.30} - 1 = 1.4 - 1 = 0.4 $$\nA bioavailability of $0.30$ instead of $0.42$ would require a $40\\%$ increase in the dose to achieve the same target steady-state concentration. This underscores the importance of carefully managing assumptions about bioavailability in early clinical development.",
            "answer": "$$\\boxed{226.3}$$"
        },
        {
            "introduction": "Ultimately, drug development aims to deliver a product that provides more benefit than risk to patients. This exercise introduces a sophisticated method for making this trade-off explicit and quantitative by using a decision-analytic utility function to select a dose for late-stage clinical trials. By combining a pharmacodynamic model for efficacy with a model for safety, you will use calculus to find the optimal dose that maximizes the overall value to the patient, reflecting a state-of-the-art, model-informed approach to drug development decision-making .",
            "id": "4598068",
            "problem": "A Phase II program for a novel oral small molecule has completed dose-ranging studies, yielding a posterior distribution over efficacy and safety parameters that will inform Phase III dose selection. The pharmacodynamic model for efficacy is assumed to follow a saturating maximum-effect form: the expected change from baseline in a continuous clinical response (for example, symptom score reduction) at dose $d$ is given by $E(d) = E_{\\max} \\times \\frac{d}{EC_{50} + d}$, where $E_{\\max}$ denotes the maximum achievable effect and $EC_{50}$ denotes the dose at which one-half of $E_{\\max}$ is achieved. The posterior mean estimates are $E_{\\max} = 2.5$ (in response units) and $EC_{50} = 60$ milligrams. Safety is summarized for the purpose of decision-making as the probability of a dose-limiting toxicity (DLT) within a fixed assessment window. For the dose range considered in Phase II ($d \\in [0,120]$ milligrams), the posterior mean safety model can be approximated as linear: $\\Pr(\\text{DLT} \\mid d) \\approx \\eta d$, with posterior mean $\\eta = 5.0 \\times 10^{-4}$ per milligram.\n\nDefine a decision-analytic utility function $U(d)$ as the weighted benefit minus weighted risk, $U(d) = w_{e} \\,\\mathbb{E}[E(d)] - w_{s} \\, C_{\\text{tox}} \\,\\mathbb{E}[\\Pr(\\text{DLT} \\mid d)]$, where $w_{e}$ and $w_{s}$ are dimensionless weights reflecting the relative importance of efficacy and safety in the targeted indication, and $C_{\\text{tox}}$ is a dimensioned scalar translating toxicity probability into the same utility scale as efficacy. For this program, set $w_{e} = 1$, $w_{s} = 1$, and $C_{\\text{tox}} = 30$ utility units per unit probability. Assume the posterior mean models above represent $\\mathbb{E}[E(d)]$ and $\\mathbb{E}[\\Pr(\\text{DLT} \\mid d)]$ in this dose range.\n\nStarting from first principles of model-based decision analysis and without invoking any shortcut formulas, derive the dose $d^{\\ast}$ that maximizes $U(d)$ over the feasible range $d \\in [0,120]$ milligrams. Express your final result for $d^{\\ast}$ in milligrams and round your answer to three significant figures.",
            "solution": "The problem requires finding the optimal dose $d^{\\ast}$ that maximizes a decision-analytic utility function $U(d)$ over a specified dose range. The problem is well-posed and scientifically grounded in the principles of pharmacometric modeling and decision analysis.\n\nThe utility function is defined as a weighted difference between the expected efficacy (benefit) and the expected safety (risk):\n$$U(d) = w_{e} \\,\\mathbb{E}[E(d)] - w_{s} \\, C_{\\text{tox}} \\,\\mathbb{E}[\\Pr(\\text{DLT} \\mid d)]$$\n\nThe expected efficacy, $\\mathbb{E}[E(d)]$, is given by a saturating maximum-effect ($E_{\\max}$) model, using the posterior mean estimates for the parameters:\n$$\\mathbb{E}[E(d)] = E_{\\max} \\times \\frac{d}{EC_{50} + d}$$\n\nThe expected probability of a dose-limiting toxicity (DLT), $\\mathbb{E}[\\Pr(\\text{DLT} \\mid d)]$, is approximated by a linear model using its posterior mean parameter:\n$$\\mathbb{E}[\\Pr(\\text{DLT} \\mid d)] = \\eta d$$\n\nSubstituting these models into the utility function gives:\n$$U(d) = w_{e} E_{\\max} \\frac{d}{EC_{50} + d} - w_{s} C_{\\text{tox}} \\eta d$$\n\nThe given values for the parameters are:\n- Efficacy weight $w_{e} = 1$\n- Safety weight $w_{s} = 1$\n- Maximum effect $E_{\\max} = 2.5$ response units\n- Half-maximal effective dose $EC_{50} = 60$ milligrams\n- Toxicity cost $C_{\\text{tox}} = 30$ utility units per unit probability\n- Toxicity slope $\\eta = 5.0 \\times 10^{-4}$ per milligram\n\nSubstituting these numerical values into the expression for $U(d)$:\n$$U(d) = (1)(2.5) \\frac{d}{60 + d} - (1)(30)(5.0 \\times 10^{-4})d$$\n$$U(d) = \\frac{2.5d}{d+60} - (150 \\times 10^{-4})d$$\n$$U(d) = \\frac{2.5d}{d+60} - 0.015d$$\n\nTo find the dose $d^{\\ast}$ that maximizes $U(d)$, we must find the critical points by taking the first derivative of $U(d)$ with respect to $d$ and setting it to zero. The optimization is performed over the feasible range $d \\in [0, 120]$ milligrams.\n\nFirst, we compute the derivative $\\frac{dU}{dd}$:\n$$\\frac{dU}{dd} = \\frac{d}{dd} \\left( \\frac{2.5d}{d+60} - 0.015d \\right)$$\nUsing the quotient rule for the first term, $\\frac{d}{dx}\\left(\\frac{u}{v}\\right) = \\frac{u'v - uv'}{v^2}$, where $u=2.5d$ and $v=d+60$:\n$$\\frac{d}{dd}\\left( \\frac{2.5d}{d+60} \\right) = \\frac{(2.5)(d+60) - (2.5d)(1)}{(d+60)^2} = \\frac{2.5d + 150 - 2.5d}{(d+60)^2} = \\frac{150}{(d+60)^2}$$\nThe derivative of the second term is:\n$$\\frac{d}{dd}(-0.015d) = -0.015$$\nCombining the terms, we get the full derivative:\n$$\\frac{dU}{dd} = \\frac{150}{(d+60)^2} - 0.015$$\n\nTo find the critical points, we set the derivative equal to zero:\n$$\\frac{150}{(d+60)^2} - 0.015 = 0$$\n$$\\frac{150}{(d+60)^2} = 0.015$$\n$$(d+60)^2 = \\frac{150}{0.015} = \\frac{150}{15/1000} = \\frac{150 \\times 1000}{15} = 10 \\times 1000 = 10000$$\nTaking the square root of both sides:\n$$d+60 = \\pm\\sqrt{10000} = \\pm 100$$\nThis yields two possible values for $d$:\n$1$. $d + 60 = 100 \\implies d = 100 - 60 = 40$\n$2$. $d + 60 = -100 \\implies d = -100 - 60 = -160$\n\nSince the dose $d$ must be a non-negative quantity, the solution $d = -160$ is not physically meaningful and is discarded. The only valid critical point is $d = 40$.\n\nTo confirm that this critical point corresponds to a maximum, we use the second derivative test. We compute the second derivative $\\frac{d^2U}{dd^2}$:\n$$\\frac{d^2U}{dd^2} = \\frac{d}{dd} \\left( \\frac{150}{(d+60)^2} - 0.015 \\right) = \\frac{d}{dd} \\left( 150(d+60)^{-2} \\right)$$\n$$\\frac{d^2U}{dd^2} = 150 \\times (-2)(d+60)^{-3} = \\frac{-300}{(d+60)^3}$$\nFor any non-negative dose $d \\ge 0$, the term $(d+60)^3$ is positive. Therefore, $\\frac{d^2U}{dd^2}$ is always negative for $d \\ge 0$. This indicates that the utility function $U(d)$ is strictly concave for all physically relevant doses, and the critical point $d = 40$ corresponds to a unique global maximum.\n\nFinally, we must check if this optimal dose lies within the feasible dose range specified in the problem, which is $d \\in [0, 120]$ milligrams. The calculated optimal dose $d^{\\ast} = 40$ is indeed within this interval. Because the function is concave and the unconstrained maximum is within the interval, it is also the maximum over that interval.\n\nThe question asks for the result to be rounded to three significant figures. The optimal dose is exactly $40$ milligrams, which is written as $40.0$ to show three significant figures of precision.",
            "answer": "$$\\boxed{40.0}$$"
        }
    ]
}